Biology subjects

Luteijn, R.

Publications and source records attributed to Luteijn, R..

3 recordsLinked to original sources

bioRxiv2025

ITAF45 is a Pervasive Trans Acting Factor for Picornavirus Type II IRES Elements

Viruses have evolved elaborate mechanisms to hijack the host mRNA translation machinery to direct viral protein synthesis. Picornaviruses, whose RNA genomes lack a cap structure, inhibit cap-dependent mRNA translation, and utilize an internal ribosome entry site (IRES) in the RNA 5'-UTR to recruit the 40S ribosomal subunit. IRES activity is stimulated by a set of host proteins termed IRES trans-acting factors (ITAFs). The cellular protein ITAF45 (also known as PA2G4 and EBP1) was identified as an essential ITAF for foot-and-mouth disease virus (FMDV), with no apparent role in cell-free systems for the closely related viruses harboring similar IRES elements such as encephalomyocarditis virus (EMCV) and Theilers murine encephalomyelitis virus (TMEV). Here, we demonstrate that ITAF45 is a pervasive host factor within cells for picornaviruses containing a Type II IRES. CRISPR/Cas9 knockout of ITAF45 in several human cell lines conferred resistance to infection with FMDV, EMCV, TMEV, and equine rhinitis A virus (ERAV). We show that ITAF45 enhances initiation of translation on type II IRESs in cell line models. This is mediated by the C-terminal lysine-rich region of ITAF45 known to enable binding to viral RNA. These findings challenge previous reports of a unique role for ITAF45 in FMDV infection, positioning ITAF45 as a promising antiviral target for various animal viruses and emerging human cardioviruses.

microbiology↗

bioRxiv2024

UFMylation suppresses Type I IFN signaling during M. tuberculosis infection of human macrophages

Type I Interferons (IFN-I) promote host defense against a wide range of viral infections, but inhibit control of several bacterial pathogens, including Mycobacterium tuberculosis (Mtb). Given the significance of IFN-I signaling in determining Mtb infection outcomes, we sought to uncover new molecular mechanisms that regulate IFN-I during mycobacterial infection, specifically focusing on how IFN-I signaling is regulated at the earliest stages of mycobacterial infection as modeled by macrophage infection. To comprehensively identify these host genes, we performed a reporter-based, genome- wide CRISPR-interference screen in human macrophages infected with Mycobacterium marinum, a close relative of Mtb. Our screen detected 2035 significantly enriched genes (p<0.05), which included many known regulators of IFN-I, but also many unexpected genes as potentially novel regulators of IFN-I signaling. One of these unexpected genes was UFL1, an E3-like ligase that catalyzes conjugation of the ubiquitin-like protein, UFM1, in a process termed UFMylation. UFL1-deficiency during Mtb macrophage infection resulted in increased expression of IFN-{beta}, interferon-stimulated genes, and other pro-inflammatory genes, such as TNF and IL-6, at both the transcript and protein level. Depletion of other UFMylation components phenocopied UFL1-deficiency, suggesting that UFMylation activity is required for IFN-I repression. Full transcriptional profiling revealed a broad increase in the inflammatory response of UFL1-deficient cells during Mtb infection, including both protective inflammatory cytokines and potentially detrimental interferon-stimulated genes. Our results suggest a role for UFMylation in suppressing IFN-I signaling and inflammatory responses during the earliest stages of Mtb infection. IMPORTANCEMycobacterium tuberculosis was estimated to have caused over 1 million deaths in 2025 - the most deaths globally by a single bacterial pathogen. Past studies in mice and humans have shown that some host immune responses, such as IFN-I signaling, can enhance susceptibility to M. tuberculosis. We report the results of our genome-wide CRISPR-interference screen to determine regulators of IFN-I signaling during the earliest stages of mycobacterial infection. This screen identified new regulators of IFN-I signaling, including the UFMylation pathway, which appears to play an unexpected role in suppressing both IFN-I signaling and a broader inflammatory response. These findings may be relevant for the development of therapeutics and prophylactics for tuberculosis that impact IFN-I signaling - a known determinant of tuberculosis susceptibility.

microbiology↗

bioRxiv2019

SLC19A1 is a cyclic dinucleotide transporter

The accumulation of DNA in the cytosol serves as a key immunostimulatory signal associated with infections, cancer and genomic damage1,2. Cytosolic DNA triggers immune responses by activating the cGAS/STING pathway3. The binding of DNA to the cytosolic enzyme cGAMP synthase (cGAS), activates its enzymatic activity, leading to the synthesis of a second messenger, cyclic[G(2,5)pA(3,5)] (23-cGAMP)4-8. 23-cGAMP, a cyclic dinucleotide (CDN), activates the protein stimulator of interferon genes (STING)9, which in turn activates the transcription factors IRF3 and NF-{kappa}B promoting the transcription of genes encoding type I interferons and other cytokines and mediators that stimulate a broader immune response. Exogenous 23-cGAMP and other CDNs, including CDNs produced by bacteria and synthetic CDNs used in cancer immunotherapy, must traverse the cell membrane to activate STING in target cells. How these charged CDNs pass through the lipid bilayer is unknown. Here we used a genome-wide CRISPR interference screen to identify the reduced folate carrier SLC19A1 as the major CDN transporter for uptake of synthetic and naturally occurring CDNs. CDN uptake and functional responses are inhibited by depleting SLC19A1 from cells and enhanced by overexpressing SLC19A1. In both cell lines and primary cells ex vivo, CDN uptake is inhibited competitively by folate and blocked by the SLC19A1 inhibitor sulfasalazine, a medication approved for the treatment of inflammatory diseases. The identification of SLC19A1 as the major transporter of CDNs into cells has far reaching implications for the immunotherapeutic treatment of cancer10, transport of 23-cGAMP from tumor cells to other immune cells to trigger the anti-tumor immune response11, host responsiveness to CDN-producing pathogenic microorganisms12, and potentially in certain inflammatory diseases.

immunology↗